Adstiladrin has BlockBuster Potential...In this link...
https://fiercepharma.com/pharma/ferring-inks-500m-deal-royalty-pharma-new-bladder-cancer-drug-adstiladrin Paragraph #7...
The CEO of Royalty Pharma, Pablo Legorreta said " Adstiladrin has BlockBuster Potential".
Adstiladrin...
- Adstiladrin has a 24%CR at 12 months.
- Adstiladrin has minimal side effects.
- Adstiladrin has one big restriction, Adstiladrin can not treat patients that are immunocompromised, that is a big restriction, because many older cancer patients are immunocompromised.
TLT-Ruvidar...
- Ruvidar has a 38%CR at 12 months(optimised patients).
- Ruvidar has minimal side effects.
- Unlike Adstiladrin, Ruvidar can treat any kind of patients including immunocompromised patients.
- And to top it off, it cost less to treat a cancer patient with Ruvidar.
As we speak ours new independant director, Dr Lbiati with these data in hand must have a pleasant time "
commencing to actively explore international partnering". According to this article Adstiladrin with 24%CR at 12 months and a big immunocompromised restriction is worth $500 milllion US.
With 38%CR at 12 months(optimised) and no restrictions, how much is TLT-Ruvidar worth $$$$$????.
You have to love the BlockBuster Potential of your TLT shares.